CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CLN-619’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CLN-619 is expected to reach an annual total of $124 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CLN-619 Overview
CLN-619 is under development for the treatment of solid tumors such as Non-small cell lung cancer, cervical cancer, ovarian cancer, head and neck cancer squamous cell carcinoma, colon cancer, prostate cancer and metastatic urothelial carcinoma. The therapeutic candidate is a anti-MICA humanized IgG1 monoclonal antibody and acts by targeting MHC class I polypeptide related sequence A (MICA) and MHC class I polypeptide related sequence B (MICB). It is administered by intravenous route.
It was also under development for liver cancer.
Cullinan Therapeutics Overview
Cullinan Therapeutics, formerly Cullinan Oncology Inc, is a clinical-stage biotechnology company that focuses on developing oncology therapies for cancer patients. Its CLN-619, is a monoclonal antibody, which treats solid tumors; CLN-049, is a humanized bispecific antibody for acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator, which targets multiple solid tumors; Zipalertinib, a bioavailable small-molecule, which treats patients with non-small cell lung cancer; CLN-617, a fusion protein for solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed or refractory B-cell non-Hodgkin lymphoma. Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$191.1 million in FY2023, compared to an operating profit of US$144.7 million in FY2022. The net loss of the company was US$153.2 million in FY2023, compared to a net profit of US$111.2 million in FY2022.
For a complete picture of CLN-619’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.